Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Costa, Luciano J. http://orcid.org/0000-0001-5362-2469
Grant, Shakira J. http://orcid.org/0000-0002-8481-3046
Kumar, Lalit
Mohty, Mohamad http://orcid.org/0000-0002-7264-808X
Aydin, Didem
Usmani, Saad Z.
Funding for this research was provided by:
Pfizer (Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable)
Article History
Received: 14 March 2023
Revised: 5 June 2023
Accepted: 15 June 2023
First Online: 18 July 2023
Competing interests
: MVM reports receiving fees derived from lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, GSK, AbbVie, Pfizer, Regeneron, Roche, Sanofi, Oncopeptides, and Seagen. SA reports providing consultancy services for GSK, Sanofi, Bristol-Myers Squibb, Takeda, Beigene, Pharmacyclics, Amgen, Janssen, AstraZeneca, and Regeneron; and receiving research support to his institution from GSK, Bristol-Myers Squibb, Pharmacyclics, Amgen, Janssen, Cellectar, Xencor, AbbVie, Medimmune, and Ascentage. LJC reports receiving honoraria from Janssen, Amgen, Sanofi, Bristol-Myers Squibb, and Adaptive Biotechnologies; participating in scientific advisory boards for Janssen, Amgen, Bristol-Myers Squibb, and Sanofi; and receiving research support from Janssen, Amgen, and Bristol-Myers Squibb. SJG reports receiving research funding from the National Cancer Institute at the National Institutes of Health (5-K12-CA120780-13 and 1 R03 AG074030-01). LK reports no conflicts of interest. MM reports receiving honoraria from or providing consultancy services to Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, Novartis, Sanofi, and Stemline; and research funding from Janssen and Sanofi. DA is an employee of and has stock or stock options in Pfizer. SZU reports receiving consulting/advisory fees, grant support, and Speakers’ Bureau fees from Amgen, Takeda, Janssen, Sanofi, and Bristol-Myers Squibb; consulting/advisory fees and grant support from Bristol-Myers Squibb, Celgene, GSK, Merck, Seattle Genetics, and Skyline Diagnostics; grant support and Speakers’ Bureau fees from Sanofi; grant support from Array BioPharma and Pharmacyclics; and consulting/advisory fees from Karyopharm Therapeutics, AbbVie, Oncopeptides, Genentech, and Gilead.